USFDA APPLICATION NUMBER - 22512 / DOSAGE - CAPSULE;ORAL - EQ 110MG BASE
Active Ingredient/Active Moiety | ||
Ingredient Name | Basis of Strength | Strength |
---|---|---|
DABIGATRAN ETEXILATE MESYLATE(UNII: SC7NUW5IIT) (DABIGATRAN - UNII:I0VM4M70GC) | DABIGATRAN | 150mg |
Inactive Ingredients
Ingredient Name | Ascend Laboratories, LLC |
---|---|
AMMONIA(5138Q19F1X) | |
BUTYLATED HYDROXYTOLUENE(1P9D0Z171K) | |
CITRIC ACID MONOHYDRATE(2968PHW8QP) | |
FD&C BLUE NO. 1(H3R47K3TBD) | |
FD&C RED NO. 40(WZB9127XOA) | |
FD&C YELLOW NO. 6(H77VEI93A8) | |
FERROSOFERRIC OXIDE(XM0M87F357) | |
HYDROXYPROPYL CELLULOSE (90000 WAMW)(UKE75GEA7F) | |
HYPROMELLOSE 2910 (6 MPA.S)(0WZ8WG20P6) | |
HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)(87Y6436BKR) | |
HYPROMELLOSE, UNSPECIFIED(3NXW29V3WO) | |
METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER(NX76LV5T8J) | |
MICROCRYSTALLINE CELLULOSE(OP1R32D61U) | |
POLYETHYLENE GLYCOL 600(NL4J9F21N9) | |
POLYETHYLENE GLYCOL, UNSPECIFIED(3WJQ0SDW1A) | |
POLYVINYL ALCOHOL, UNSPECIFIED(532B59J990) | |
POTASSIUM HYDROXIDE(WZH3C48M4T) | |
POVIDONE K25(K0KQV10C35) | |
PROPYLENE GLYCOL(6DC9Q167V3) | |
SHELLAC(46N107B71O) | |
SODIUM BICARBONATE(8MDF5V39QO) | |
TALC(7SEV7J4R1U) | |
TARTARIC ACID(W4888I119H) | |
TITANIUM DIOXIDE(15FIX9V2JP) |
LOOKING FOR A SUPPLIER?